GLIX1, a treatment for recurrent and progressive glioblastoma and other high-grade gliomas, has begun human testing in a Phase 1/2a clinical trial, said…

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to the experimental therapy ZW191 as a potential treatment for hard-to-manage ovarian cancer.

A European Medicines Agency (EMA) panel has recommended approval of a subcutaneous (under-the-skin) version of Sarclisa (isatuximab), an approved myeloma treatment sold by Sanofi. The…